id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-D-3124-0025,FDA,FDA-2018-D-3124,"Adaptive Designs for Clinical Trials of Drugs and Biologics; Guidance for
Industry; Availability",Notice,Notice of Availability,2019-12-02T05:00:00Z,2019,12,2019-12-02T05:00:00Z,2020-01-03T04:59:59Z,2020-05-04T17:31:30Z,2019-25986,0,0,09000064841d6538
FDA-2018-D-3124-0026,FDA,FDA-2018-D-3124,Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry,Other,Guidance,2019-12-02T05:00:00Z,2019,12,2019-12-02T05:00:00Z,2020-01-03T04:59:59Z,2024-11-12T23:13:42Z,,1,0,09000064841d715a
FDA-2018-D-3124-0001,FDA,FDA-2018-D-3124,Adaptive Designs for Clinical Trials of Drugs and Biologics; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,2018-12-01T04:59:59Z,2018-12-02T02:01:52Z,2018-21314,0,0,0900006483785d84
FDA-2018-D-3124-0002,FDA,FDA-2018-D-3124,Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2024-11-12T06:18:33Z,,1,0,090000648378696f